DS Healthcare Group Reports Second Quarter 2013 Results
Record revenues of $7,400,000 for the first half of the year
Pompano Beach, Aug. 20, 2013 (GLOBE NEWSWIRE) -- DS Healthcare Group, Inc.
(NASDAQ:DSKX), a leading developer of personal care products, today announced
results for the three and six months ended June 30, 2013.
Net revenues increased 35% for the first six months of 2013 to $7,392,846,
over revenues of $5,482,244 in the same period of 2012. Revenue growth was
primarily due to the acquisition of the Company's Mexican subsidiary and
carryover of unfilled orders from the fourth quarter of 2012. Gross profits
for the six months ended June 30, 2013 increased by 35% to $3,375,769 as
compared to $2,501,081 in the same period of 2012. Net loss attributable to
shareholders during the six months ended June 30, 2013 was $(1,125,056) or
$(0.10) per basic and diluted share, as compared to $(808,423) or $(0.08) per
basic and diluted share in the same period of 2012.
Net revenues for the second quarter of 2013 were $3,431,154, a 2% decline from
revenues of $3,498,262 in the second quarter of 2012. Revenues decreased
slightly due to the Company's new policies related to extending credit to new
and existing customers, preventing the Company from shipping some goods on its
schedule. Gross profits increased by 10% to $1,601,087 in the second quarter
of 2013, as compared to $1,450,761 in the second quarter of fiscal 2012. Net
loss attributable to shareholders in the second quarter of 2013 was $(757,063)
or $(0.06) per basic and diluted share as compared to $(368,086) or $(0.03)
per basic and diluted share in the second quarter of 2012. .
The Company reported total current assets of $8,042,076 and total
shareholders' equity of $3,204,332 on June 30, 2013.
"In the first half of 2013 we have achieved record revenues. We continue to
launch new products and expand further into promising new markets like Brazil,
through our distribution partner and Mexico, through our newly acquired
Mexican subsidiary. There is tremendous enthusiasm in the market for our
products and we strive to deliver more products to more people to meet their
needs. Our customers have a passion for our products because they are
extremely effective. We reported results from a clinical study we concluded
during the second quarter which showed that our Spectral.DNC-S is effective in
the promotion of healthy hair and in the cessation of thinning hair in males.
We are optimistic about the remainder of 2013 as we continue to execute on a
tremendous market opportunity," stated DS Healthcare President and CEO Daniel
About DS Healthcare Group
DS Healthcare Group Inc. leads in the development and distribution of topical
therapies for personal care, including what management believes is the world's
most effective topical treatment for hair loss. Its products are sold through
a network of salons, pharmacies, online retailers, specialty retailers and
select department stores. Its brands include DS Laboratories
(www.DSLaboratories.com), Sigma Skin (www.(www.SigmaSkin.com), Polaris
Research Laboratories (www.PolarisResearchLabs.com) The Pure Guild
(www.ThePureGuild.com) and Nutra Origin (www.NutraOrigin.com)
Except for statements of historical fact, the matters discussed in this press
release are forward-looking and made pursuant to the Safe Harbor provisions of
the Private Securities Litigation Reform Act of 1995. "Forward-looking
statements" describe future expectations, plans, results, or strategies, and
are generally preceded by words such as "future," "plan" or "planned,"
"expects," or "projected." These forward-looking statements reflect numerous
assumptions and involve a variety of risks and uncertainties, many of which
are beyond the company's control that may cause actual results to differ
materially from stated expectations. These risk factors include, among others,
limited operating history, difficulty in developing and marketing products,
intense competition, and additional risks factors as discussed in reports
filed by the company with the Securities and Exchange Commission, which are
available at http://www.sec.gov.
Press spacebar to pause and continue. Press esc to stop.